GlassScriptPhysician profile
Thomas M Chandler
NPI 1568429223
$9,095.47
in general payments reported to CMS, 2019-2025
43 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $1,001 · 2021: $815 · 2022: $1,047 · 2023: $1,524 · 2024: $1,793 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,672 · Education: $11.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,672.30 |
| Education | $11.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,101.59 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,066.06 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Electromed, INC. | $803.90 | 2022-2025 | Smartvest |
| Insmed, INC. | $735.66 | 2019-2025 | Arikayce, Brinsupri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $722.04 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $351.27 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $332.99 | 2019-2023 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $313.75 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $246.81 | 2019-2025 | Zerbaxa, Keytruda, Capvaxive |
| Mylan Specialty L.P. | $202.18 | 2019-2022 | |
| Grifols USA, LLC | $199.83 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Covidien LP | $179.63 | 2019 | |
| Harmony Biosciences LLC | $171.80 | 2020-2025 | Wakix |
| Ani Pharmaceuticals, INC. | $171.34 | 2024-2025 | Purified Cortrophin Gel |
| Philips North America LLC | $168.82 | 2019-2025 | Vest Therapy Und |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chandler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.